This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Small-Cap Winners & Losers

Small-cap stocks underperformed the tumbling broad indices for the second straight session Tuesday despite several bouts of good news out of the health-care sector.

Xoma (XOMA), for instance, vaulted 17.5% after saying it has licensed to Pfizer (PFE) nonexclusive rights to its patented antibody technology. Pfizer will pay the Berkeley, Calif., company $30 million cash upfront for the bacterial cell expression technology in addition to "milestone, royalty and other fees on future sales of all products subject to this license, including products currently in late-stage clinical development." Xoma shares soared 40 cents to $2.68. Pfizer slipped 1.5% to $24.39.

Omrix Biopharmaceuticals (OMRI) jumped 16.5% to $33.86 after the Food and Drug Administration approved the New York-based company's Evithrom product -- a blood-clotting protein indicated for use during surgery.

Elsewhere in the health-care market, Advanced Life Sciences (ADLS) said the FDA granted orphan drug designation (for drugs that treat rare diseases) to its ALS-357 compound for the topical treatment of metastatic melanoma, a type of skin cancer.

That designation makes ALS-357 eligible for seven-year exclusivity on approval, in addition to potential tax credits, R&D grant funding and other benefits. Shares of the Woodridge, Ill., company climbed 6.7% to $1.76.

Perceptron (PRCP), which makes measurement and inspection technology primarily for the automotive industry, also had a quick rise on positive fiscal fourth-quarter financials. The Plymouth, Mich., company said it swung to a profit of $2.3 million, or 26 cents a share, on sales that surged 61.3% year over year to $23.4 million. Shares lately gained 11.7% to $11.62.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs